GHRP-2 (Pralmorelin)
GHRP-2 raised food intake by 10.2% at low dose and 33.5% at high dose versus placebo (PMID 16861611; checked 24 Aug 2026). The double-blind crossover had 19 people. GH also rose with dose. PubMed lists no grant. The abstract has no table of adverse events. These findings belong to GHRP-2, not GHRP-2-Gly.
Which names and identifiers belong to GHRP-2?
GSRS gives the names PRALMORELIN and GROWTH HORMONE-RELEASING PEPTIDE 2 (GSRS; checked 24 Aug 2026). It gives UNII E6S6E1F19M and CAS 158861-67-7.
GHRP-2 is a six-part drug that can release GH. GHRP-2-Gly has one more glycine at the start and is a different compound.
What did the 19-person trial measure?
Ten lean and nine obese adults took part in three visits set by chance (PMID 16861611; checked 24 Aug 2026).
| Comparison with placebo | Result | Primary source |
|---|---|---|
| Low-dose food intake | +10.2 ± 3.9%; p = 0.011 | PMID 16861611 |
| High-dose food intake | +33.5 ± 5.8%; p < 0.001 | PMID 16861611 |
| Growth hormone | Dose-dependent increase | PMID 16861611 |
Lean and obese adults had the same food response. The abstract has no full table of adverse events. PubMed lists no grant. Full-paper funding was not checked.
What did the seven-person crossover measure?
Seven healthy men ate 35.9 ± 10.9% more with GHRP-2 than with saline (PMID 15699539; p = 0.008; checked 24 Aug 2026). GH rose from 412 ± 161 to 5,550 ± 1,090 µg/L per 240 minutes. The abstract has no adverse-event table. PubMed lists no grant.
What longer human record is available?
One case report followed nasal GHRP-2 for one year in severe anorexia nervosa (PMID 26401470; checked 24 Aug 2026). Weight rose 6.7 kg in 14 months. The report saw no clear side effects. One case does not prove a controlled effect.
What does evidence tier B mean here?
Small human studies with controls measured food and GH. Tier B stays right (checked 24 Aug 2026). The tier belongs only to GHRP-2. It does not move to the glycine form.
What is the recorded EU status?
The EU Commission index has no exact entry for GHRP-2 or Pralmorelin (Union Register index; checked 24 Aug 2026). The EU field stays unclear.
When was GHRP-2 first observed in a product?
PMID 20878896 came out in March 2010 and found about 50 µg of GHRP-2 in each supplement tablet. It supports 2010-03 as a publication by-date (checked 24 Aug 2026).
What does this register entry cover?
This entry covers GHRP-2 human evidence and identity. It does not cover GHRP-2-Gly.
→ GHRP-2-Gly register entry → What can be in a vial → All register entries